Welcome to our dedicated page for Outlook Therapeutics news (Ticker: OTLK), a resource for investors and traders seeking the latest updates and insights on Outlook Therapeutics stock.
Outlook Therapeutics, Inc. develops and commercializes ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab for retina diseases, including wet age-related macular degeneration. Company news commonly covers the product’s European Commission and MHRA marketing authorizations, commercial launch activity in Germany, Austria and the UK, and U.S. regulatory communications involving the biologics license application pathway for neovascular AMD.
Updates also include capital-structure actions used to fund operations, such as public offerings, registered direct offerings, warrants, convertible-note amendments and note financing. Governance and shareholder-approval matters appear in connection with securities issuance and authorized-share requirements.
Outlook Therapeutics, Inc. (Nasdaq: OTLK) announced that its President, CEO, and CFO, Lawrence A. Kenyon, will present at the Virtual Investor Fireside Chat Series on June 17, 2020, at 2:00 PM ET. The event aims to discuss the company’s progress in developing the first FDA-approved ophthalmic formulation of bevacizumab for retinal indications such as wet AMD and DME. A live Q&A session will follow, allowing attendees to interact directly with management. A webcast replay will be available two hours post-event for one year.
Outlook Therapeutics (OTLK) announced the closing of a $16 million private placement of common stock priced at $1.00 per share, a 34% premium. The funds will be directed towards working capital and its development program for ONS-5010, an investigational ophthalmic formulation aimed at treating wet AMD. The company will also contribute $0.9 million to a planned 80%-owned joint venture in China with Syntone Ventures to commercialize ONS-5010. Outlook Therapeutics aims for FDA approval to be the first approved ophthalmic formulation of bevacizumab.
Outlook Therapeutics, Inc. (Nasdaq: OTLK) has entered a Stock Purchase Agreement with Syntone Ventures for a $16 million private placement of common stock at $1.00 per share, aimed at advancing the development of its investigational drug ONS-5010 / LYTENAVA™. A joint venture will also be formed with Syntone Technologies to develop ONS-5010 in China. The Company plans to utilize $0.9 million from this funding to support the joint venture and expects additional contributions in the coming years. The deal may enhance the commercialization potential of its product.